immunological pathogenesis
Recently Published Documents


TOTAL DOCUMENTS

19
(FIVE YEARS 4)

H-INDEX

8
(FIVE YEARS 2)

2020 ◽  
Vol 12 (2) ◽  
Author(s):  
Gianluca Cuomo ◽  
Marianna Menozzi ◽  
Federica Carli ◽  
Margherita Digaetano ◽  
Alessandro Raimondi ◽  
...  

We describe a case of acute myocarditis which was reported as the main COVID-19 clinical manifes-tation, with a favorable outcome. In addition to symptoms, laboratory tests (BNP and troponin), echo-cardiogram and cardiac MRI contributed to diagnosis. Regardless heart biopsy was not obtained, it is likely an immunological pathogenesis of this condition which pave the way to further therapeutic im-plications, since there are currently no standardized treatments.


2020 ◽  
Vol 8 ◽  
pp. 232470962091479 ◽  
Author(s):  
Ivy Riano ◽  
Cagney Cristancho ◽  
Thomas Treadwell

Stevens-Johnson syndrome (SJS) is a life-threating mucocutaneous reaction predominantly induced by drugs. Targeted cancer therapies such as pembrolizumab, which has been approved for the treatment of metastatic malignancy, can cause severe skin toxicities, including SJS. They are rare and inconsistently reported. In this article, we report the case of a 80-year-old woman with metastatic non–small cell lung cancer who had a SJS-like eruption involving oral mucosa after 15 weeks of exposure of pembrolizumab (6 doses) and 7 days after 1 dose of recombinant zoster vaccine. SJS is a rare blistering disorder with high mortality rate and significant morbidity. Causes include drugs, herpes viruses, and immunization. The timing of the eruption soon after the receipt of recombinant zoster vaccine suggests a role of vaccination in our patient, yet patients receiving cancer immunotherapy may develop late-onset skin toxicity. Therefore, we recommend long-term monitoring for mucocutaneous reactions after initiation of pembrolizumab. Further research is needed to characterize the immunological pathogenesis and improve timely recognition and treatment strategies.


2019 ◽  
Vol 10 ◽  
Author(s):  
Wenbin Liu ◽  
Chang Gao ◽  
Haoran Dai ◽  
Yang Zheng ◽  
Zhaocheng Dong ◽  
...  

2019 ◽  
Vol 16 (1) ◽  
pp. 19-30 ◽  
Author(s):  
Lu Pan ◽  
Mei-Ping Lu ◽  
Jing-Hua Wang ◽  
Meng Xu ◽  
Si-Rui Yang

2018 ◽  
Vol 16 (1) ◽  
pp. 26 ◽  
Author(s):  
Seung Hoon Lee ◽  
Jeong eun Kwon ◽  
Mi-La Cho

2015 ◽  
Vol 17 (1) ◽  
pp. 29-31 ◽  
Author(s):  
Fangping Yang ◽  
Ying Yang ◽  
Qinyuan Zhu ◽  
Sheng-an Chen ◽  
Xiaodan Fu ◽  
...  

2014 ◽  
Vol 18 (5) ◽  
pp. 749-758 ◽  
Author(s):  
Min Li ◽  
Lu‐Jun Song ◽  
Xin‐Yu Qin

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Elena Giacomini ◽  
Maria Elena Remoli ◽  
Marta Scandurra ◽  
Valérie Gafa ◽  
Manuela Pardini ◽  
...  

Knowledge of the molecular events regulating the innate response toMycobacterium tuberculosis(Mtb) is critical for understanding immunological pathogenesis and protection from tuberculosis. To this aim, the regulation and the expression of regulatory and proinflammatory cytokines were investigated in human primary monocytes upon Mtb infection. We found that Mtb-infected monocytes preferentially express a proinflammatory cytokine profile, including IL-6, TNF-α, and IL-1β. Conversely, among the regulatory cytokines, Mtb elicited IL-10 and IL-23 release while no expression of IL-12p70, IL-27, and IFN-βwas observed. The analysis of the signalling pathways leading to this selective cytokine expression showed that in monocytes Mtb activates MAPK and NF-κB but is unable to stimulate IRF-3 phosphorylation, a transcription factor required for IL-12p35 and IFN-βgene expression. Thus, by inducing a specific cytokine profile, Mtb can influence the immunoregulatory properties of monocytes, which represent important target of novel vaccinal strategies against Mtb infection.


2010 ◽  
Vol 1 (2) ◽  
pp. 112-121 ◽  
Author(s):  
P.O. Lang ◽  
W.A. Mitchell ◽  
A. Lapenna ◽  
D. Pitts ◽  
R. Aspinall

Sign in / Sign up

Export Citation Format

Share Document